• Je něco špatně v tomto záznamu ?

Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE

R. Schilling, GS. Dhillon, C. Tondo, S. Riva, M. Grimaldi, F. Quadrini, P. Neuzil, GB. Chierchia, C. de Asmundis, A. Abdelaal, L. Vanderlinden, T. Tan, WY. Ding, D. Gupta, VY. Reddy

. 2021 ; 23 (6) : 851-860. [pub] 20210607

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025601

AIMS: To evaluate the safety and effectiveness of a compliant multi-electrode radiofrequency balloon catheter (RFB) used with a multi-electrode diagnostic catheter for pulmonary vein isolation (PVI). METHODS AND RESULTS: This prospective, multicentre, single-arm study was conducted at six European sites and enrolled patients with symptomatic paroxysmal atrial fibrillation. The primary effectiveness endpoint was entrance block in treated pulmonary veins (PVs) after adenosine/isoproterenol challenge. The primary safety endpoint was the occurrence of primary adverse events (PAEs) within 7 days. Cerebral magnetic resonance imaging and neurological assessments were performed pre- and post-ablation in a subset of patients. Atrial arrhythmia recurrence was assessed over 12 months via transtelephonic and Holter monitoring. Quality of life was assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. Of 85 patients undergoing ablation per study protocol, PV entrance block was achieved in all (one PV required touch-up with a focal catheter). Acute reconnection of ≥1 PVs after adenosine/isoproterenol challenge was observed in 9.3% (30/324) of PVs ablated. Post-ablation, silent cerebral lesions were detected in 9.7% (3/31) of patients assessed, all of which was resolved at 1-month follow-up. One patient experienced a PAE (retroperitoneal bleed). Freedom from documented symptomatic and all arrhythmia was 72.2% and 65.8% at 12 months. Four patients (4.7%) underwent repeat ablation. Significant improvements in all AFEQT subscale scores were seen at 6 and 12 months. CONCLUSION: PVI with the novel RFB demonstrated favourable safety and effectiveness, with low repeat ablation rate and clinically meaningful improvement in quality of life. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT03437733.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025601
003      
CZ-PrNML
005      
20211026133650.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euaa382 $2 doi
035    __
$a (PubMed)33450010
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Schilling, Richard $u Department of Cardiology, St. Bartholomew's Hospital, W Smithfield, London EC1A 7BE, UK
245    10
$a Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE / $c R. Schilling, GS. Dhillon, C. Tondo, S. Riva, M. Grimaldi, F. Quadrini, P. Neuzil, GB. Chierchia, C. de Asmundis, A. Abdelaal, L. Vanderlinden, T. Tan, WY. Ding, D. Gupta, VY. Reddy
520    9_
$a AIMS: To evaluate the safety and effectiveness of a compliant multi-electrode radiofrequency balloon catheter (RFB) used with a multi-electrode diagnostic catheter for pulmonary vein isolation (PVI). METHODS AND RESULTS: This prospective, multicentre, single-arm study was conducted at six European sites and enrolled patients with symptomatic paroxysmal atrial fibrillation. The primary effectiveness endpoint was entrance block in treated pulmonary veins (PVs) after adenosine/isoproterenol challenge. The primary safety endpoint was the occurrence of primary adverse events (PAEs) within 7 days. Cerebral magnetic resonance imaging and neurological assessments were performed pre- and post-ablation in a subset of patients. Atrial arrhythmia recurrence was assessed over 12 months via transtelephonic and Holter monitoring. Quality of life was assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. Of 85 patients undergoing ablation per study protocol, PV entrance block was achieved in all (one PV required touch-up with a focal catheter). Acute reconnection of ≥1 PVs after adenosine/isoproterenol challenge was observed in 9.3% (30/324) of PVs ablated. Post-ablation, silent cerebral lesions were detected in 9.7% (3/31) of patients assessed, all of which was resolved at 1-month follow-up. One patient experienced a PAE (retroperitoneal bleed). Freedom from documented symptomatic and all arrhythmia was 72.2% and 65.8% at 12 months. Four patients (4.7%) underwent repeat ablation. Significant improvements in all AFEQT subscale scores were seen at 6 and 12 months. CONCLUSION: PVI with the novel RFB demonstrated favourable safety and effectiveness, with low repeat ablation rate and clinically meaningful improvement in quality of life. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT03437733.
650    12
$a fibrilace síní $x diagnóza $x chirurgie $7 D001281
650    12
$a katetrizační ablace $x škodlivé účinky $7 D017115
650    _2
$a katétry $7 D057785
650    _2
$a elektrody $7 D004566
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    12
$a venae pulmonales $x diagnostické zobrazování $x chirurgie $7 D011667
650    _2
$a kvalita života $7 D011788
650    _2
$a recidiva $7 D012008
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Dhillon, Gurpreet Singh $u Department of Cardiology, St. Bartholomew's Hospital, W Smithfield, London EC1A 7BE, UK
700    1_
$a Tondo, Claudio $u Monzino Cardiology Center, University of Milan, Via Carlo Parea, 4, 20138 Milano MI, Italy
700    1_
$a Riva, Stefania $u Monzino Cardiology Center, University of Milan, Via Carlo Parea, 4, 20138 Milano MI, Italy
700    1_
$a Grimaldi, Massimo $u Department of Cardiology, Ospedale Generale Regionale "F. Miulli", Strada Prov. 127 Acquaviva-Santeramo Km. 4, 70021 Acquaviva delle Fonti BA, Italy
700    1_
$a Quadrini, Federico $u Department of Cardiology, Ospedale Generale Regionale "F. Miulli", Strada Prov. 127 Acquaviva-Santeramo Km. 4, 70021 Acquaviva delle Fonti BA, Italy
700    1_
$a Neuzil, Petr $u Department of Cardiology, Na Homolce Hospital, Roentgenova 37, 150 00 Praha 5, Czechia
700    1_
$a Chierchia, Gian-Battista $u Heart Rhythm Management Center, Universitair Ziekenhuis Brussels, Avenue du Laerbeek 101, 1090 Jette, Belgium
700    1_
$a de Asmundis, Carlo $u Heart Rhythm Management Center, Universitair Ziekenhuis Brussels, Avenue du Laerbeek 101, 1090 Jette, Belgium
700    1_
$a Abdelaal, Ahmed $u Biosense Webster, Inc, 29b Technology Dr, Irvine, CA, USA
700    1_
$a Vanderlinden, Liesbeth $u Biosense Webster, Inc, 29b Technology Dr, Irvine, CA, USA
700    1_
$a Tan, Tiffany $u Biosense Webster, Inc, 29b Technology Dr, Irvine, CA, USA
700    1_
$a Ding, Wern Yew $u Liverpool Heart and Chest Hospital, Thomas Dr, Liverpool L14 3PE, UK
700    1_
$a Gupta, Dhiraj $u Liverpool Heart and Chest Hospital, Thomas Dr, Liverpool L14 3PE, UK
700    1_
$a Reddy, Vivek Y $u Department of Cardiology, Na Homolce Hospital, Roentgenova 37, 150 00 Praha 5, Czechia $u Department of Electrophysiology, Division of Cardiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, USA
773    0_
$w MED00149837 $t Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology $x 1532-2092 $g Roč. 23, č. 6 (2021), s. 851-860
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33450010 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133656 $b ABA008
999    __
$a ok $b bmc $g 1714584 $s 1146108
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 6 $d 851-860 $e 20210607 $i 1532-2092 $m Europace $n Europace $x MED00149837
LZP    __
$a Pubmed-20211013
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace